Drugs / JNJ-79635322
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06768489 | Dec 2024 → Jan 2029 expected | AL amyloidosis, smoldering plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05652335 | Nov 2022 → Apr 2027 expected | AL amyloidosis, refractory plasma cell neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07266441 | Feb 2026 → Jun 2027 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06500884 | Aug 2024 → May 2030 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT05695508 | Dec 2022 → Sep 2028 expected | plasma cell myeloma | University of Heidelberg Medical Center | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07665450 | Sep 2026 → Sep 2030 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07518186 | May 2026 → Apr 2029 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07258511 | Feb 2026 → Dec 2028 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07589634 Background | Jun 2026 → Dec 2027 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | Janssen Research & Development, LLC | Results Johnson & Johnson presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancing the potential for cure jnj.com ↗
Updated safety and efficacy data for ramantamig (JNJ-5322), an investigational BCMA and GPRC5D trispecific antibody, at the recommended Phase 2 dose, with new data demonstrating feasibility of outpatient dosing in patients with relapsed or refractory multiple myeloma (Abstract #OA-70) |
| 2025-06-03 | Janssen Research & Development, LLC | Results Early results from Johnson & Johnson’s trispecific antibody show promising response in heavily pretreated multiple myeloma patients jnj.com ↗
Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent. |
| 2025-06-03 | Janssen Research & Development, LLC | Results Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients jnj.com ↗
Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | Janssen Research & Development, LLC | Johnson & Johnson presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancing the potential for cure jnj.com ↗ |
| 2025-06-03 | Janssen Research & Development, LLC | Early results from Johnson & Johnson’s trispecific antibody show promising response in heavily pretreated multiple myeloma patients jnj.com ↗ |
| 2025-06-03 | Janssen Research & Development, LLC | Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients jnj.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-79635322 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05695508 ↗ |
| Known as | Ramantamig | “Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody” PMID 41100731 ↗ Feb 2026 |
| Action | Deplete | “resulting in efficient depletion of the malignant clonal populations” PMID 41100731 ↗ Feb 2026 |
| Route | Subcutaneous | “JNJ-79635322 will be administered as SC injection.” NCT05652335 ↗ |
| Target | GPRC5D | “targeting BCMA, GPRC5D, and CD3” PMID 41100731 ↗ Feb 2026 |